Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report) today. The company’s ...
Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 ...
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...
Five-year data from the POETYK PSO long-term extension trial confirm the sustained efficacy and safety of Sotyktu ...
Incisive reports from four areas of bloody conflict ? Sudan, the Russian-Ukraine war zone, Israel's West Bank and Haiti ? are among 15 winners of the George Polk Awards for 2024 announced today by ...
US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...
The Internet is Leaking: Public Dashboard Tracks Billions of Exposed Assets and Secrets in Real Time
RedHunt Labs has introduced a real-time Internet Attack Surface Dashboard, tracking millions of exposed assets, leaked credentials, and misconfigured cloud services daily. With 18M+ new subdomains, 3, ...
No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...
European leaders trying to make sense of a tough new line from Washington on issues including democracy and Ukraine’s future ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback